← All trials
NCT05650528
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 28, 2023
- Primary completion
- Feb 29, 2024
- Completion date
- Jun 30, 2024
- First posted
- Dec 14, 2022
- Last posted
- Dec 14, 2022
- Enrollment
- 64
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Amckaus PTY LTD.Lead sponsor
- NovotechCollaborator
- CMAX Clinical ResearchOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.